Donnerstag, 2. Mai 2024
Navigation öffnen
Anzeige:
Wefra Programatic
 
JOURNAL ONKOLOGIE – STUDIE
SwissNET

SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

Rekrutierend

NCT-Nummer:
NCT01039922

Studienbeginn:
Januar 2008

Letztes Update:
23.01.2020

Wirkstoff:
-

Indikation (Clinical Trials):
Neoplasms, Neuroendocrine Tumors, Carcinoid Tumor

Geschlecht:
Alle

Altersgruppe:
Alle

Phase:
-

Sponsor:
Insel Gruppe AG, University Hospital Bern

Collaborator:
Cantonal Hospital of St. Gallen, University Hospital, Basel, Switzerland, University Hospital, Geneva, University of Lausanne Hospitals, University Hospital, Zürich, Triemlispital Zurich, Spitalnetz Bern, Ente Ospedaliero Cantonale, Bellinzona, Luzerner Kantonssp

Studienleiter

Aurel Perren, MD
Study Director
Institute of Pathology, University of Bern, Bern

Kontakt

Studienlocations
(3 von 55)

Bezirksspital Affoltern
Affoltern am Albis
SwitzerlandRekrutierend» Google-Maps
Istituto oncologico della Svizzera italiana
Bellinzona
SwitzerlandRekrutierend» Google-Maps
Div. of Endocrinology, Diabetes and Clinical Nutrition, Bern University Hospital
3010 Bern
SwitzerlandRekrutierend» Google-Maps
Private practise Dr. Mannhart
Churwalden
SwitzerlandRekrutierend» Google-Maps
Hôpitaux Universitaires de Genève
Geneva
SwitzerlandRekrutierend» Google-Maps
Centre hospitalier universitaire vaudois, CHUV
Lausanne
SwitzerlandRekrutierend» Google-Maps
Kantonsspital Münsterlingen
Münsterlingen
SwitzerlandRekrutierend» Google-Maps
Gesundheitszentrum Fricktal
Rheinfelden
SwitzerlandRekrutierend» Google-Maps
Centre hospitalier du centre du Valais
Sion
SwitzerlandRekrutierend» Google-Maps
Alle anzeigen

Studien-Informationen

Detailed Description:

Background

Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are generally classified as rare

diseases. Little is known about their cell biology and their mechanistic regulation. During

the last years, the incidence of GEP-NETs is continuously increasing worldwide. In parallel,

novel treatment options are currently evaluated which may substantially improve prognosis of

patients with NETs. Data on such tumours in Switzerland, however, is scarce and treatment

strategies vary throughout the country.

Objective

To systematically and prospectively collect clinical information of patients with GEP-NETs in

Switzerland based on a histologically confirmed diagnosis.

Methods

All NETs of both, gastrointestinal and pulmonary origin are included provided that patients

have given informed consent. Data will be entered prospectively and anonymised in a

specifically designed database. Contributing centres and general practitioners are visited by

a study nurse, patient files are analysed and data is transferred to the database. In case of

conflicting evidence, questions are resolved in collaboration with a review board of

SwissNET. Evaluation of treatment modalities and patient outcomes (e.g. mortality,

hospitalisation rate) will take place within regular time frames.

Ein-/Ausschlusskriterien

Inclusion Criteria:

- Neuroendocrine tumor irrespective of primary tumor location

- Diagnosis in Switzerland

- Given informed consent

Studien-Rationale

Primary outcome:

1. Tumor-related mortality (Time Frame - Every 5 years)



Secondary outcome:

1. Incidence of GEP-NET in Switzerland (Time Frame - Every 5 years)

2. Effect of specific treatment strategies (Time Frame - Every 5 years)

Quelle: ClinicalTrials.gov


Sie können folgenden Inhalt einem Kollegen empfehlen:

"SwissNET - a Registry for Neuroendocrine Tumours in Switzerland"

Bitte tragen Sie auch die Absenderdaten vollständig ein, damit Sie der Empfänger erkennen kann.

Die mit (*) gekennzeichneten Angaben müssen eingetragen werden!

Die Verwendung Ihrer Daten für den Newsletter können Sie jederzeit mit Wirkung für die Zukunft gegenüber der MedtriX GmbH - Geschäftsbereich rs media widersprechen ohne dass Kosten entstehen. Nutzen Sie hierfür etwaige Abmeldelinks im Newsletter oder schreiben Sie eine E-Mail an: rgb-info[at]medtrix.group.